Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...
Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care. This year in retina is almost ...
During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy. As imaging modalities improve, so do ...
Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...
In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed ...
In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...
Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes. Now is an exciting time to be a ...
Neurotech Pharmaceuticals performs the first ENCELTO procedure. Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only ...
Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination. Topcon Healthcare, Inc, announced it has ...
Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...
Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025. To strengthen Opus Genetics’ gene therapy program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback